Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
基本信息
- 批准号:8881036
- 负责人:
- 金额:$ 52.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-30 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAged, 80 and overAgingAntibodiesAntiphospholipid AntibodiesAutopsyBloodBlood - brain barrier anatomyBlood VesselsBlood specimenBrainC-reactive proteinCardiolipinsCell physiologyCerebrovascular DisordersCessation of lifeClinicalCognitionCognitiveCohort StudiesCommunitiesConsensusDataDiseaseElderlyEpidemiologic StudiesEpidemiologyGlycoproteinsGoalsHealthHigh PrevalenceImpaired cognitionImpairmentInfarctionInflammationInternationalIschemic StrokeKnowledgeLinkLiteratureMagnetic Resonance ImagingMatrix MetalloproteinasesMeasuresMediatingMemoryMicroscopicMotorNeurologicNeurologic DysfunctionsNeuropsychological TestsOutcomePathologicPathway interactionsPerformancePermeabilityPersonsPrevalencePublic HealthResearch PersonnelRiskRoleSerineStrokeSystemic Lupus ErythematosusTestingTimeWhite Matter HyperintensityWomanaging populationcerebrovascularclinical practicecognitive functioncohortdisabilitydisorder controlfollow-upimprovedinflammatory markermenmortalitymotor disordermotor impairmentnervous system disorderneuroimagingneuropathologytrendvascular factor
项目摘要
PROJECT SUMMARY:
Cerebrovascular disease is among the most common neurological diseases of aging and is increasing in
prevalence with changing demographic trends. The two most common consequences of cerebrovascular
disease are cognitive and motor decline, which are major contributors to poor health outcomes and mortality.
Identifying associated factors, particularly ones for which treatments are available, is a priority for researchers
in aging. Recent data suggest that antiphospholipid antibodies (aPL) increase in aging, and are present in
about 35% of persons over the age of 80 years. While aPL increase risk of stroke by about two-fold, their
relation to decline in cognitive and motor function, perhaps through an association with both clinical and
subclinical cerebrovascular disease, is unclear. The proposed epidemiologic study will take advantage of a
cohort of 1,100 community-dwelling women and men who are followed longitudinally with a high follow-up rate,
and who come to autopsy with a high autopsy rate (R01AG17917), to test the hypotheses that aPL are related
to cognitive and motor decline. The study will also examine the relation of aPL to cerebrovascular disease,
including subclinical cerebrovascular disease assessed by complementary ante-mortem neuroimaging and
postmortem neuropathology, and the extent to which aPL are related to cognitive and motor impairment after
controlling for this disease. This would suggest the existence of neurobiologic mechanisms other than
cerebrovascular disease linking aPL and cognitive and motor dysfunction. Finally, because factors with effects
other than vascular may influence relations, the study will examine the role of makers of inflammation and
altered blood-brain barrier permeability. The proposed study, relating aPL and other markers to cognitive and
motor decline, and cerebrovascular disease in older, community-dwelling persons, will provide new knowledge
regarding the role of aPL in common neurological conditions of aging. Because aPL are common vascular
factors for which treatments are available, this study will provide new data which has the potential to improve
public health by shifting current clinical practice paradigms and reducing the burden of neurological disease in
aging.
项目总结:
脑血管疾病是最常见的老年神经系统疾病之一,在
患病率随着人口趋势的变化而变化。脑血管疾病最常见的两种后果
疾病是认知和运动能力下降,这是造成不良健康结果和死亡率的主要原因。
确定相关因素,特别是那些可以治疗的因素,是研究人员的优先事项。
在衰老过程中。最近的数据表明,抗磷脂抗体(APL)随着年龄的增长而增加,并存在于
大约35%的80岁以上的人。虽然APL使中风的风险增加了大约两倍,但他们的
与认知和运动功能下降的关系,可能是通过与临床和
亚临床脑血管疾病,目前尚不清楚。拟议的流行病学研究将利用
由1100名居住在社区的男女组成的队列,他们被纵向跟踪,随访率很高,
并以高尸检率(R01AG17917)前来尸检,以检验APL相关的假设
认知和运动能力下降。这项研究还将探讨APL与脑血管疾病的关系,
包括亚临床脑血管疾病的辅助死前神经成像和
死后神经病理,以及APL与认知和运动障碍的关系
控制这种疾病。这可能表明存在着除
将APL与认知和运动功能障碍联系起来的脑血管疾病。最后,因为有影响的因素
除了血管可能影响关系,这项研究将检查炎症和
血脑屏障通透性改变。拟议的研究,将APL和其他标记物与认知和
老年社区居民的运动能力下降和脑血管疾病将提供新的知识
关于APL在常见的神经衰老状况中的作用。因为APL是常见的血管
对于可用治疗的因素,这项研究将提供有潜力改进的新数据
通过改变当前的临床实践模式和减轻神经性疾病的负担来实现公共卫生
衰老。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zoe Arvanitakis其他文献
Zoe Arvanitakis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zoe Arvanitakis', 18)}}的其他基金
Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4
大脑 cPLA2 作为 AD/ADRD 神经炎症的机制,有或没有 APOE4
- 批准号:
10464564 - 财政年份:2022
- 资助金额:
$ 52.74万 - 项目类别:
The role of blood and brain 5-hydroxymethylcytosine in linking vascular risk factors to ADRD in older White and Black persons
血液和脑 5-羟甲基胞嘧啶在老年白人和黑人血管危险因素与 ADRD 之间的联系中的作用
- 批准号:
10315659 - 财政年份:2021
- 资助金额:
$ 52.74万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8336938 - 财政年份:2011
- 资助金额:
$ 52.74万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8728095 - 财政年份:2011
- 资助金额:
$ 52.74万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8526334 - 财政年份:2011
- 资助金额:
$ 52.74万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8234526 - 财政年份:2011
- 资助金额:
$ 52.74万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
7556333 - 财政年份:2005
- 资助金额:
$ 52.74万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
7007680 - 财政年份:2005
- 资助金额:
$ 52.74万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
7367080 - 财政年份:2005
- 资助金额:
$ 52.74万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
6868496 - 财政年份:2005
- 资助金额:
$ 52.74万 - 项目类别:














{{item.name}}会员




